MA08.083n, Leuprolide (Camcevi™, Camcevi ETM®, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross Medicare Advantage added ICD-10 code F64.A (Gender identity disorder, in remission) as NOT medically necessary for leuprolide acetate products (J1950, J9217, J1951, J1952), effective 10/01/2026. This exclusion means claims for leuprolide with this diagnosis code will be denied. The policy also clarifies preferred vs. nonpreferred leuprolide products, with preferred products (Eligard, Lupron Depot 7.5 mg) designated for prostate cancer and salivary gland tumors.